Literature DB >> 14871843

Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.

Monica Simeoni1, Paolo Magni, Cristiano Cammia, Giuseppe De Nicolao, Valter Croci, Enrico Pesenti, Massimiliano Germani, Italo Poggesi, Maurizio Rocchetti.   

Abstract

The available mathematical models describing tumor growth and the effect of anticancer treatments on tumors in animals are of limited use within the drug industry. A simple and effective model would allow applying quantitative thinking to the preclinical development of oncology drugs. In this article, a minimal pharmacokinetic-pharmacodynamic model is presented, based on a system of ordinary differential equations that link the dosing regimen of a compound to the tumor growth in animal models. The growth of tumors in nontreated animals is described by an exponential growth followed by a linear growth. In treated animals, the tumor growth rate is decreased by a factor proportional to both drug concentration and number of proliferating tumor cells. A transit compartmental system is used to model the process of cell death, which occurs at later times. The parameters of the pharmacodynamic model are related to the growth characteristics of the tumor, to the drug potency, and to the kinetics of the tumor cell death. Therefore, such parameters can be used for ranking compounds based on their potency and for evaluating potential differences in the tumor cell death process. The model was extensively tested on discovery candidates and known anticancer drugs. It fitted well the experimental data, providing reliable parameter estimates. On the basis of the parameters estimated in a first experiment, the model successfully predicted the response of tumors exposed to drugs given at different dose levels and/or schedules. It is, thus, possible to use the model prospectively, optimizing the design of new experiments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871843     DOI: 10.1158/0008-5472.can-03-2524

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  148 in total

1.  WebPK, a web-based tool for custom pharmacokinetic simulation.

Authors:  Jaydeep Srimani; Richard A Moffitt; May D Wang
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2010

2.  General relationship between transit compartments and lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-23       Impact factor: 2.745

Review 3.  Prediction of exposure-response relationships to support first-in-human study design.

Authors:  John P Gibbs
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

Review 4.  Pharmacodynamic models of age-structured cell populations.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-16       Impact factor: 2.745

Review 5.  Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.

Authors:  Alan V Boddy
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

6.  Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.

Authors:  Sophie Callies; Valérie André; Bharvin Patel; David Waters; Paul Francis; Michael Burgess; Michael Lahn
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

7.  Steering the Clinical Translation of Delivery Systems for Drugs and Health Products.

Authors:  Rosario Pignatello; Pietro Matricardi
Journal:  Pharmaceutics       Date:  2020-04-13       Impact factor: 6.321

8.  Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.

Authors:  Qiong Wu; Meng-yao Li; Han-qing Li; Chen-hui Deng; Liang Li; Tian-yan Zhou; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2013-10-07       Impact factor: 6.150

9.  Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

Authors:  Shinji Yamazaki
Journal:  AAPS J       Date:  2012-12-19       Impact factor: 4.009

10.  Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Authors:  Jun Yang; Donald E Mager; Robert M Straubinger
Journal:  AAPS J       Date:  2009-11-10       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.